In c4239 transmitted on Monday, September 19, 2011 by Cloud Dx, the
company designation as Cloud Dx was incorrect. Corrected copy follows:
Biosign Response to Annual Shareholder Meeting Questions
SAN FRANCISCO, Sept. 19, 2011 /CNW/ - Biosign Technologies Inc. (TSXV:
BIO), a medical device company focused on non-invasive, cloud-based
vital health monitoring, held its annual shareholders meeting last
week. All matters of business as described in the Information Circular
were approved, including the election of Steven Bloom to the Board of
Directors and the ratification of the company's employee stock option
Dr. Scott Jenkins, CEO of the company, reviewed with shareholders the
patient and disease management market globally and provided an overview
of the competitive landscape. Dr. Jenkins also announced Cloud Dx, a
division of Biosign, is launching a business model for reducing the
cost of healthcare utilization by providing an active cloud-based vital
health monitoring system that allows providers to deliver the best
quality of care to patients. A copy of Dr. Jenkins' presentation can be
found at: http://www.biosign.com/news.htm.
Steven Bloom was elected to the Board of Directors and subsequently
appointed by the board as the Chair of the Audit Committee. Mr. Bloom
is the Senior Vice President, Finance at Kilmer Van Nostrand Co.
Limited. He has served in various financial leadership positions,
including Partner and Chief Financial Officer, Brightspark Capital;
Chief Financial Officer, Think Dynamics; Vice President, Finance,
Descartes Systems Group; and Manager, Ernst and Young.
Mr. Bloom is a Chartered Accountant and holds an Honors of Business
Administration degree from the University of Western Ontario-Richard
Ivey School of Business.
"We are very fortunate to have Steven Bloom on our board," says Dr.
Jenkins, CEO. "Steven's extensive and diverse financial experience will
benefit our Audit Committee and bring a fresh perspective to the
In addition to the approval of the employee stock option plan, 300,000
stock options were granted to a director on September 12, 2011,
pursuant to the company's stock option plan at an exercise price of $
0.74 per share.
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Cloud
Dx applications include intelligent systems for non-invasive monitoring
of common health risks associated with blood pressure, glucose, and
medication. Biosign technology combines measurement, analysis, and
tools for disease and patient management to support global vital health
monitoring. The UFIT® medical device delivers quality data collection
and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For
more information visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign/Cloud Dx Contact: